No Data
Evercore Maintains Carisma Therapeutics(CARM.US) With Buy Rating, Maintains Target Price $4
Evercore ISI Remains a Buy on Carisma Therapeutics (CARM)
Carisma Unveils Pre-Clinical Data On Anti-GPC3 In Vivo CAR-M Therapy For Hepatocellular Carcinoma Developed In Collaboration With Moderna
Express News | Carisma -Anti-Gpc3 in Vivo Car-M Therapy Well Tolerated in Mouse Models, Highlighting Its Potential as an off--Shelf Treatment for Gpc3+ Solid Tumors
EF Hutton Maintains Buy on CARISMA Therapeutics, Maintains $24 Price Target
CARISMA Therapeutics Q3 2024 GAAP EPS $(0.31) Misses $(0.24) Estimate, Sales $3.38M Miss $5.47M Estimate
No Data
No Data